Abbott Molecular Inc. Sustainability Profile
Abbott Molecular Inc., a subsidiary of Abbott Laboratories, is a leading player in the global diagnostics industry, headquartered in the United States. Founded in 2007, the company has rapidly established itself as a pioneer in molecular diagnostics, focusing on innovative solutions for infectious diseases, oncology, and genetic testing. With a strong presence in North America, Europe, and Asia, Abbott Molecular offers a diverse range of products, including advanced molecular assays and diagnostic platforms. Their unique approach combines cutting-edge technology with a commitment to accuracy and efficiency, setting them apart in a competitive market. Recognised for their contributions to healthcare, Abbott Molecular has achieved significant milestones, including the development of groundbreaking tests that enhance patient care. Their dedication to innovation and quality positions them as a trusted leader in the molecular diagnostics sector.
DitchCarbon Score
How does Abbott Molecular Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abbott Molecular Inc.'s score of 54 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Abbott Molecular Inc., headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Abbott Laboratories, which may influence its climate commitments and reporting practices. While Abbott Molecular Inc. has not set specific reduction targets or initiatives, it is important to note that emissions data and climate strategies may be inherited from its parent company, Abbott Laboratories. Abbott Laboratories has established various climate initiatives, including commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). However, specific details regarding these initiatives and their impact on Abbott Molecular Inc.'s emissions profile are not disclosed. As a subsidiary, Abbott Molecular Inc. may align its climate strategies with those of Abbott Laboratories, which could include broader industry-standard climate terminology and practices. Without specific emissions data or reduction targets, the company's climate commitments remain vague, but it is positioned within a corporate family that is actively engaged in sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 578,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 691,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - | - | 0,000,000,000 |
How Carbon Intensive is Abbott Molecular Inc.'s Industry?
How Carbon Intensive is Abbott Molecular Inc.'s Location?
Abbott Molecular Inc.'s Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 71% of Scope 3 emissions.
Top Scope 3 Categories
Abbott Molecular Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Abbott Molecular Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
